Langmu has been listed in the market for 4 years, breaking the precedent repeatedly, and wants to become the "China core" of biomedical industry

[China Pharmaceutical network enterprise news] Kanghong pharmaceutical industry, with its fist in hand, is shouldering a greater mission According to its 2017 annual report, in 2017, the company achieved revenue of 2.786 billion yuan and net profit of 644 million yuan, with a year-on-year growth of 9.7% and 29.68% respectively, which is the third year in which the company's net profit maintained a growth of more than 20% after listing in 2015 In fact, in recent years, Kanghong pharmaceutical industry has become a model of domestic innovative pharmaceutical enterprises by virtue of the innovative drug benchmark of Ramu (conbercept) Behind its outstanding performance is the strong support of the innovative drug According to Kanghong pharmaceutical, Lanmu has been on the market since April 2014, with a cumulative sales volume of more than 1.5 billion At present, Lanmu accounts for more than half of the market share in the treatment of wet age-related macular degeneration However, as a biological innovative drug directly entering the phase III clinical research of FDA in the history of China's pharmaceutical industry, Lamu is still looking forward to a bigger stage; On the other hand, with the emergence of trade frictions between China and the United States, the voice of the industry for the "China core" in the field of biomedical industry is increasingly strong, and Lamu also carries more missions - the "great power and heavy weapon" that dominates the global market Kanghong pharmaceutical is one of the pharmaceutical companies that have followed the principle of "no R & D, no future" since its establishment In 2017, Kanghong pharmaceutical realized operating revenue of 2.786 billion yuan, net profit of 644 million yuan and net profit of 6227 million yuan, with year-on-year growth of 9.7%, 29.68% and 28.67% respectively Since its listing, Kanghong pharmaceutical industry has maintained a rapid growth in performance According to Kanghong pharmaceutical's annual report, the company's operating revenue in recent years has been bullish year by year In 2014, the annual operating revenue was 1.675 billion yuan In 2015, it exceeded the 2 billion mark, and by 2017, it had risen to 2.786 billion yuan From 2015 to 2017, the revenue growth of Kanghong pharmaceutical industry was 23.88%, 22.45% and 9.7% respectively, and the net profit growth was 44%, 26.14% and 29.68% respectively It is worth noting that behind the beautiful performance mentioned above, we can't do without the strong support of the fist product, Langmu As a representative of China's innovative drugs, Lamu has also pioneered in many aspects since its launch in 2014 For example, according to the public data, in July 2016, the terminal price of the world pharmaceutical giant Novartis pharmaceutical's heavyweight product, leizhumab, in China was reduced from 9800 yuan / piece to 7200 yuan / piece, with a price reduction of 2600 yuan / piece, a drop of 26%, which is only two years from the listing of Ramu in China In addition, in the second quarter of 2016, Ramu's market share has reached 52% In addition to forcing competitors to reduce prices, Kanghong pharmaceutical also disclosed in October 2016 that Lanmu has been approved by the U.S Food and Drug Administration (FDA) and can directly enter phase III clinical trials in the United States Langmu has become the first innovative drug in the history of China's pharmaceutical industry that has directly entered the phase II clinical research of FDA in the United States It is also the first Chinese biological drug that has obtained FDA's clinical approval (ind) Langmu's courage is not enough In July last year, the Ministry of human resources and social security released a list of 36 drugs that were successfully included in the category B directory of the 2017 version of the basic medical insurance drug directory through negotiation, and the Langmu R & D and production of Kanghong pharmaceutical industry was clearly listed What shocked the industry was that in the drug price negotiation, Kanghong pharmaceutical Langmu's medical insurance payment standard was 5550 yuan, which was only 18.38% lower than the average retail price of 6800 yuan issued by the Ministry of human resources and social security The analysis shows that the unique competitiveness of Ramu is behind the breakthrough At the special meeting of major new drug innovation held by the State Council in May 2017, the national leadership asked song Ruilin, executive chairman of China pharmaceutical promotion association, "how many innovative drugs in China can be internationally recognized?" the latter replied, "since the launch of major national projects, China has set up 1558 major projects, and 21 class a new drugs have been successfully approved, but they can be internationally recognized There are only 5 vaccines, 2 vaccines and 3 preparations, among which Ramulus is representative " It is by virtue of this unique competitiveness that Lamu's market recognition has also reached a new high After the disclosure of 2017 annual report by Kanghong Pharmaceutical Co., Ltd., including the research reports issued by Zhongtai securities, it is believed that the net profit margin of Langmu is expected to continue to increase to steady-state 40% in the future In fact, as early as Lamu was approved to enter the medical insurance catalog, there was a research report of securities companies that believed that it could grow into more than 2 billion varieties Kanghong pharmaceutical does not intend to stop here if it wants to be a "great power and heavy weapon" for the above achievements Various signs show that it is further developing the length and width of Ramu In May 2017, Lamu's new indication "decreased vision caused by choroidal neovascularization (pmcnv) secondary to pathological myopia (PM)" was approved According to the research report, it is estimated that about 1.6 million new patients with this indication will be approved, and the market space will be expanded by 50% compared with the current 3 million patients with Wamd indication In addition, Langmu is also an approved product for pmcnv indication in the current domestic fundus neovascularization market What makes the market more concerned is the future layout of Lamu in the international market Recently, the "ZTE banned in the US" incident against the background of Sino US trade friction has aroused heated discussion in the biomedical industry The consensus in the industry is that "innovative medicine" is enough to pry the global market, and "innovative medicine" will also be used as a "major power" in the field of biomedicine in the future to enhance the voice, and only industrial independence can ensure the realization of "healthy China" strategy As for Kanghong pharmaceutical, "to be the Chinese medicine" is its mission since its establishment Ke Zunhong, chairman of Kanghong Pharmaceutical Co., Ltd., also firmly believes that "as a big country, the health of a nation cannot be controlled by other countries." The firm belief makes the rapid report after the listing of Lamu In October 2016, Kanghong Pharmaceutical Co., Ltd was approved to pass through FDA phase III clinical trials; in October 2017, Kanghong Pharmaceutical Co., Ltd spent more than 1.5 billion yuan to hire cro company for FDA phase III trials; On April 20 this year, Kanghong pharmaceutical announced that its wholly-owned subsidiary Chengdu Kanghong Biotechnology Co., Ltd received a letter from the FDA on the review and approval of the special scheme for the clinical trial of neovascular age-related macular degeneration carried out in the United States by conbercept vitreous cavity ophthalmic injection Ke Zunhong once said, "a person can't do many things in his life, and the same is true for an enterprise You have to focus on your positioning and development direction, so Kanghong's positioning is very clear It's my dream and Kanghong's dream to be able to achieve two or three products that go global." This dream needs high R & D investment support According to the 2017 annual report, its R & D investment reached 349 million yuan in the reporting period, accounting for 12.56% of the total revenue, while the proportion of R & D investment of many domestic pharmaceutical enterprises in the same period was about 1% Dream has set sail, is sailing into a broader ocean Original title: Langmu has been listed in the market for 4 years, breaking through the precedent repeatedly to become the "China core" of biomedical industry